Alterity Therapeutics seeks shareholder approval for CEO David Stamler's termination benefits
ATHE•Alterity Therapeutics will seek shareholder approval at its upcoming annual general meeting for termination benefits for CEO and Managing Director David Stamler, as part of a revised remuneration package approved by the board effective October 15, 2026.
1. Approval sought
Alterity Therapeutics will seek shareholder approval at its upcoming annual general meeting for termination benefits for CEO and Managing Director David Stamler. The benefits are part of a revised remuneration package approved by the board effective October 15, 2026.
